| Literature DB >> 30682322 |
Vytaute Starkuviene1,2, Stefan M Kallenberger1,3, Nina Beil1, Tautvydas Lisauskas1, Bastian So-Song Schumacher1, Ruben Bulkescher1, Piotr Wajda1, Manuel Gunkel1, Jürgen Beneke1, Holger Erfle1.
Abstract
Due to high associated costs and considerable time investments of cell-based screening, there is a strong demand for new technologies that enable preclinical development and tests of diverse biologicals in a cost-saving and time-efficient manner. For those reasons we developed the high-density cell array (HD-CA) platform, which miniaturizes cell-based screening in the form of preprinted and ready-to-run screening arrays. With the HD-CA technology, up to 24,576 samples can be tested in a single experiment, thereby saving costs and time for microscopy-based screening by 75%. Experiments on the scale of the entire human genome can be addressed in a real parallel manner, with screening campaigns becoming more comfortable and devoid of robotics infrastructure on the user side. The high degree of miniaturization enables working with expensive reagents and rare and difficult-to-obtain cell lines. We have also optimized an automated imaging procedure for HD-CA and demonstrate the applicability of HD-CA to CRISPR-Cas9- and RNAi-mediated phenotypic assessment of the gene function.Entities:
Keywords: CRISPR-Cas9 gene editing; EGF endocytosis; KIF27; cell arrays; phenotypic screening
Mesh:
Substances:
Year: 2019 PMID: 30682322 DOI: 10.1177/2472555218818757
Source DB: PubMed Journal: SLAS Discov ISSN: 2472-5552 Impact factor: 3.341